CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 6, 2013, Pages 466-474

  Li, Dan Ying ^a   Teng, Rui Chen ^b   Zhu, Huai Jun ^a   Fang, Yun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

18B; 3; Calcineurin inhibitors; CYP3A4; CYP3A5; Haplotype; Renal transplantation

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG TRANSPORT; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; HAPLOTYPE; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CHINA; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TACROLIMUS;

EID: 84878808239     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201836     Document Type: Article

References (30)

1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000; 342: 605-612. doi:10.1056/NEJM200003023420901 PubMed (Pubitemid 30118412)
2. Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther. 2006; 112: 184-198. doi:10.1016/j.pharmthera.2006.04.006 PubMed (Pubitemid 44301492)
3. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007; 2: 374-384. doi:10.2215/CJN.03791106 PubMed
4. Tang C, Lin JH, Lu AY. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? Drug Metab Dispos. 2005; 33: 603-613. doi:10.1124/dmd.104.003236 PubMed (Pubitemid 40593872)
5. Thervet E, Anglicheau D, Legendre C, Beaune P. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit. 2008; 30: 143-150. doi:10.1097/FTD.0b013e31816babef PubMed (Pubitemid 351521640)
6. Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant. 2005; 5: 207-217. doi:10.1111/j.1600- 6143.2005.00748.x PubMed (Pubitemid 40179507)
7. Roy JN, Barama A, Poirier C, Vinet B, Roger M. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics. 2006; 16: 659-665. doi:10.1097/01.fpc. 0000220571.20961.dd PubMed (Pubitemid 44223077)
8. Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, Eap CB. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit. 2008; 30: 689-699. doi:10.1097/FTD.0b013e31818a2a60 PubMed
9. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002; 54: 1271-1294. doi:10.1016/S0169-409X(02)00066-2 PubMed
10. Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant. 2005; 19: 638-643. doi:10.1111/j.1399-0012.2005.00370.x PubMed (Pubitemid 41341696)
11. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther. 2007; 81: 228-234. doi:10.1038/sj.clpt.6100039 PubMed (Pubitemid 46174820)
12. Suzuki Y, Homma M, Doki K, Itagaki F, Kohda Y. Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects. Br J Clin Pharmacol. 2008; 66: 154-155. doi:10.1111/j.1365-2125.2008.03162.x PubMed (Pubitemid 351822158)
13. Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplant Proc. 2008; 40: 1690-1695. doi:10.1016/j.transproceed.2008.04.010 PubMed (Pubitemid 351853194)
14. Chu XM, Hao HP, Wang GJ, Guo LQ, Min PQ. Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients. Acta Pharmacol Sin. 2006; 27: 1504-1508. doi:10.1111/j.1745-7254.2006.00428.x PubMed
15. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Hanai S, Nakajima T, Matsumoto K, Saito H, Goto Y, Kimura H, Katoh M, Sugai K et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat. 2004; 23: 100. doi:10.1002/humu.9210 PubMed
16. Hu YF, Tu JH, Tan ZR, Liu ZQ, Zhou G, He J, Wang D, Zhou HH. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica. 2007; 37: 315-327. doi:10.1080/00498250601149206 PubMed (Pubitemid 46442598)
17. Zeng Y, He YJ, He FY, Fan L, Zhou HH. Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects. Acta Pharmacol Sin. 2009; 30: 478-484. doi:10.1038/aps.2009. 27 PubMed
18. Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, Zhang L, Zhong MK. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol. 2008; 64: 1069-1084. doi:10.1007/s00228-008-0520-8 PubMed
19. Qiu F, He XJ, Sun YX, Li-Ling J, Zhao LM. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients. Pharmacol Rep. 2011; 63: 815-825. PubMed
20. Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. J Clin Pharm Ther. 2011; 36: 614-624. doi:10.1111/j.1365-2710.2010.01206.x PubMed
21. Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, He L, Shi Y. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009; 19: 519-523. doi:10.1038/cr.2009.33 PubMed
22. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005; 15: 97-98. doi:10.1038/sj.cr.7290272 PubMed (Pubitemid 41653949)
23. Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, Paul LC, de Fijter JW. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005; 67: 2440-2447. doi:10.1111/j.1523-1755.2005.00352.x PubMed (Pubitemid 41623408)
24. Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB, Angelini A, Alaibac M, Bontorin M, Calzolari D, Peserico A, Thiene G, Iliceto S, Gerosa G. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transpl Int. 2005; 18: 116-124. doi:10.1111/j.1432-2277.2004.00001.x PubMed (Pubitemid 41742955)
25. Iversen M, Nilsson F, Sipponen J, Eiskjaer H, Mared L, Bergan S, Nyström U, Fagertun HE, Solbu D, Simonsen S. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study. J Heart Lung Transplant. 2009; 28: 919-926. doi:10.1016/j.healun.2009.05.022 PubMed
26. Schrauder A, Saleh S, Sykora KW, Hoy H, Welte K, Boos J, Hempel G, Grigull L. Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough. Pediatr Transplant. 2009; 13: 444-450. doi:10.1111/j.1399-3046.2008.00968.x PubMed
27. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker MR, Alloway RR, Meibohm B. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 2003; 43: 555-564. PubMed (Pubitemid 36613114)
28. Min DI, Ellingrod VL, Marsh S, McLeod H. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit. 2004; 26: 524-528. doi:10.1097/00007691-200410000-00010 PubMed (Pubitemid 39314320)
29. Pei Yun ping FY, Wang Yu, Ji Cheng. Monitoring Indexes of Plasma CsA Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation. China Pharmacy. 2008; 19: 584-586.
30. Davies RA, Veinot JP, Williams K, Haddad H, Baker A, Donaldson J, Pugliese C, Struthers C, Masters RG, Hendry PJ, Mesana T. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients. Transplant Proc. 2007; 39: 3334-3339. doi:10.1016/j.transproceed.2007.08.109 PubMed (Pubitemid 350251491)